177Lu-RM2 has also demonstrated feasibility and safety with high uptake in tumor and rapid clearance from normal organs in mCRPC patients with inadequate PSMA expression or lower PSMA accumulation following prior 177Lu-PSMA-617 treatment [86]. This evidence concerns the gene FOLH1 and neoplasm.